The erm(41) gene confers inducible macrolide resistance in Mycobacterium abscessus subsp. abscessus, calling into question the usefulness of macrolides for treating M. abscessus subsp. abscessus infections. With an extended incubation (14 days), isolates with MICs of >8 g/ml are considered macrolide resistant by current CLSI guidelines. Our goals were to determine the incidence of macrolide susceptibility in U.S. isolates, the validity of currently accepted MIC breakpoints, and the erm(41) sequences associated with susceptibility. Of 349 isolates (excluding those with 23S rRNA gene mutations), 85 (24%) had clarithromycin MICs of <8 g/ml. Sequencing of the erm(41) genes from these isolates, as well as from isolates with MICs of >16 g/ml, including ATCC 19977 T , revealed 10 sequevars. The sequence in ATCC 19977 T was designated sequevar (type) 1; most macrolide-resistant isolates were of this type. Seven sequevars contained isolates with MICs of >16 g/ml. The T28C substitution in erm(41), previously associated with macrolide susceptibility, was identified in 62 isolates (18%) comprising three sequevars, with MICs of <2 (80%), 4 (10%), and 8 (10%) g/ml. No other nucleotide substitution was associated with macrolide susceptibility. We recommend that clarithromycin susceptibility breakpoints for M. abscessus subsp. abscessus be changed from <2 to <4 g/ml and that isolates with an MIC of 8 g/ml have repeat MIC testing or erm sequencing performed. Our studies suggest that macrolides are useful for treating approximately 20% of U.S. isolates of M. abscessus subsp. abscessus. Sequencing of the erm gene of M. abscessus subsp. abscessus will predict inducible macrolide susceptibility.
T
hree closely related taxa of rapidly growing mycobacteria (RGM) with a controversial species/subspecies status, i.e., Mycobacterium abscessus subsp. abscessus, "M. abscessus subsp. massiliense," and M. abscessus subsp. bolletii, comprise the heterogeneous M. abscessus group (1, 2) . A 2013 phylogenetic analysis based on genomic sequencing corroborated previous recommendations that the three taxa should be separated into three subspecies (3) . Of these three subspecies, M. abscessus subsp. abscessus and M. abscessus subsp. bolletii, a relatively rare subspecies in the United States, demonstrate the presence of inducible macrolide resistance conferred by a novel erm gene, erm(41) (4) .
In contrast, the erm(41) gene is generally present in isolates of M. abscessus subsp. massiliense but contains a large, 397-bp deletion (that includes position 28T) that results in a nonfunctional erm(41) gene, and thus isolates do not show inducible macrolide resistance (2) .
In 2009, Nash and colleagues described two strains (MAB30 and MC1028) of M. abscessus subsp. abscessus which contained a nonfunctional erm gene (4); the strains were not inducibly resistant to clarithromycin, and even after extended incubation, they demonstrated susceptible clarithromycin MICs. The loss of function of the erm genes was associated with a T-to-C substitution at position 28 of the gene (T28C), leading to an amino acid change from Trp to Arg at codon 10 (4). Such strains are categorized as the MAB30 subgroup.
The presence of erythromycin ribosomal methylase (erm) genes has called into question the usefulness of macrolides for treatment of infections caused by some RGM, including M. abscessus subsp. abscessus (4) . The prevalence of the MAB30 subgroup among U.S. isolates and their 14-day clarithromycin MICs have not been well studied. A relatively high prevalence would indicate that macrolides still have a role in therapy for M. abscessus subsp. abscessus disease. An initial evaluation of the MAB30 subgroup showed some isolates to have 14-day clarithromycin MICs of 4 g/ml (considered intermediate in the current CLSI guidelines) and 8 g/ml (considered resistant). Therefore, we initiated a study of these isolates of M. abscessus subsp. abscessus with clarithromycin MICs of 8 g/ml or less following extended incubation.
(A portion of this study was presented at the 114th General Meeting of the American Society for Microbiology [5] .) Clarithromycin broth microdilution MIC testing. Susceptibility testing was performed using the CLSI-recommended broth microdilution MIC method (9) . Clarithromycin MICs were determined initially after 3 days and then daily (except on weekends) for up to 14 days of incubation at 30°C. Current CLSI MIC breakpoints for clarithromycin were utilized, i.e., Յ2 g/ml (susceptible), 4 g/ml (intermediate), and Ն8 g/ml (resistant), to assess the susceptibility of the isolates. Isolates with macrolide resistance at the initial reading were considered resistant on the basis of a 23S rRNA gene mutation, not due to an inducible erm gene, and were excluded from the study (4, 10) .
MATERIALS AND METHODS

Isolates
Nucleotide sequence accession numbers. Representative sequences of each erm gene sequevar (1 to 10) have been deposited in GenBank under consecutive accession numbers KP676133 through KP676142.
RESULTS
Isolates.
A total of 357 isolates of M. abscessus subsp. abscessus collected between February 2009 and September 2012, plus one isolate collected in November 2014, were identified by hsp65 PRA and/or rpoB gene sequencing and underwent antimicrobial susceptibility testing.
erm(41) gene sequence. Nine erm gene sequevars closely related to the sequence of the M. abscessus subsp. abscessus type strain, ATCC 19977 (10 total), were identified and numbered sequevars 2 to 10 ( Table 1) . No erm gene sequevars consistent with the other M. abscessus subspecies were identified among these isolates. Multiple single nucleotide polymorphisms (SNPs) (range of 2 to 8) were noted in all but one sequevar (type 8, which has a single SNP). The SNPs are listed in Table 2 .
Isolates with MICs of Ͼ16 g/ml were associated with seven of the sequevars (sequevars 1, 4, and 6 to 10), although the majority of these macrolide-resistant isolates (approximately two-thirds) had a sequevar or type 1 erm(41) gene sequence identical to that of the type strain (ATCC 19977). The seven macrolide-resistant sequevars all had a thymine (T) at position 28.
Of the total of 358 isolates, 85 had clarithromycin MICs of Յ8 g/ml (Table 1) . Sixty-two of the 85 (73%) isolates with clarithromycin MICs of Յ8 g/ml belonged to the three sequevars (i.e., 2, 3, and 5) with the characteristic T28C substitution (i.e., MAB30 subgroup isolates). This substitution was previously associated with functional loss of the erm gene and susceptibility to clarithromycin. No isolates with an MIC of Ͼ8 g/ml had this base substitution. Sixty of the 62 (97%) isolates that had the T28C substitution had a sequevar 2 erm gene that matched the MAB30 sequence previously described by Nash et al. (4) . The type 2 erm sequence exhibited a 4-bp difference from the sequevar 1 sequence, but the 3 bp other than bp 28 (C) were found in other sequevars that consisted of macrolide-resistant isolates. No base pair difference from the type 1 sequevar, other than T28C, was associated with loss of function of the gene.
Clarithromycin broth microdilution MIC testing. Nine of the 358 isolates (2.5%) had MICs of Ͼ16 g/ml at 3 to 5 days of incubation, were presumed to have mutational macrolide resistance, and were excluded. As stated above, 85 of the remaining 349 wild-type isolates (24%) had MICs of Յ8 g/ml. Table 1 shows the MIC ranges for these 85 isolates and their erm sequevar types. Of the remaining 264 isolates, with MICs of Ͼ16 g/ml, the modal time for detection of clarithromycin resistance was 14 days, with a range of 8 to 14 days.
Susceptibilities of the 60 type 2 erm gene sequevar (MAB30) isolates revealed 48 (80%) with MICs of Յ2 g/ml, 6 (10%) with an MIC of 4 g/ml, and 6 (10%) with an MIC of 8 g/ml (Table 1) . Repeat testing was performed on the six isolates with an MIC of 8 g/ml, and all had clarithromycin MICs of Յ2 g/ml. Of the six isolates of M. abscessus subsp. abscessus with an MIC of 4 g/ml, five showed repeat clarithromycin MICs of Յ2 g/ml (one isolate still had an MIC of 4 g/ml after testing was repeated twice).
Sixteen of 85 (19%) isolates with MICs of Յ8 g/ml (4 with MICs of Յ2 g/ml, 2 with an MIC of 4 g/ml, and 9 with an MIC of 8 g/ml) had a type 1 erm sequevar (lacked the T28C substitution). On repeat testing, 11 had MICs of Ն16 g/ml, 1 still had a 
a Sequevar present in the type strain, ATCC 19977. b NA, not applicable.
clarithromycin MIC of 8 g/ml, and 1 had an MIC of 2 g/ml (3 other isolates were not available for repeat testing).
DISCUSSION
Macrolides have remained the cornerstone of therapy for most nontuberculous mycobacterial (NTM) infections (11 The finding of the erm(41) gene in M. abscessus subsp. abscessus isolates has evoked major questions about the utility of macrolides against these isolates and may explain the lack of efficacy of macrolide-based regimens against this group (especially for chronic lung disease) (15) . Using the current CLSI clarithromycin breakpoints of Յ2 g/ml (susceptible), 4 g/ml (intermediate), and Ն8 g/ml (resistant), based on 3 days of incubation (9), 73% of the 358 clinical isolates from the United States demonstrated inducible clarithromycin resistance (14-day MICs of Ն16 g/ml) (the majority of which appeared to result from the presence of the erm type 1 sequevar, including in ATCC 19977 T ) (5, 9). In contrast, 85 of the isolates of M. abscessus subsp. abscessus had MICs of Յ8 g/ml after extended incubation. Sequencing of the erm gene in isolates of M. abscessus subsp. abscessus (24%) revealed 10 sequevars, although only those associated with a T28C substitution (primarily of the type 2 sequevar) were found to be nonfunctional and showed extended-incubation clarithromycin MICs of Յ4 g/ ml. The type 2 sequevar corresponded to the MAB30 subgroup isolates previously described by Nash et al. (4) .
In accordance with the findings in this study, wild-type (untreated) isolates of M. abscessus subsp. abscessus with a type 1 erm sequevar matching that of ATCC 19977 T or one of the six other, less frequently encountered erm gene sequences of sequevar types 4 and 6 to 10, associated with clarithromycin MICs of Ͼ16 g/ml, should be considered macrolide resistant. Isolates with the type 2 erm sequevar (MAB30), as well as types 3 and 5 (all three of which contain the T28C substitution), should be considered macrolide susceptible. Sequencing of the erm gene is an especially important diagnostic tool for assessment of clarithromycin susceptibility in isolates of M. abscessus subsp. abscessus which have equivocal MICs of 4 to 8 g/ml. In the current study, 73% of the isolates of M. abscessus subsp. abscessus with clarithromycin MICs of Յ8 g/ml had a T28C mutation (previously associated with loss of function of the erm gene), and 60/62 (97%) isolates matched the previously described MAB30 strain (type 2 erm sequevar) (4).
The T28C mutation leads to a Trp (hydrophobic aromatic side chain)-to-Arg (positively charged side chain) amino acid substitution. This change would be expected to have a significant impact on protein structure and function and thus is consistent with the absence of resistance in the type 2 sequevar isolates. Although there are several other missense polymorphisms (i.e., exchanging one amino acid for another), all but one represent changes to comparable amino acids, mostly replacing one aliphatic residue with another. The remaining change of Gln to Pro in sequevars 3 and 5 would most likely also have a minimal impact on the protein, unless this was in a catalytic site, since both of these amino acids have hydrophobic regions in their side chains. Intriguingly, the 12 type 2 erm sequevar isolates with an MIC of 4 or 8 g/ml exhibited MICs of Յ2 g/ml on repeat testing, for all but 1 isolate. The interpretation of MICs after extended incubation is not without pitfalls. This difference in MICs with repeat testing is thought to be due partially to the difficulty in interpreting macrolide MICs after extended incubation and, in some cases, to the poor growth of some isolates in broth. Previously treated isolates can sometimes produce suboptimal growth in the current susceptibility broth (i.e., Mueller-Hinton broth). However, a more enriched broth, such as Middlebrook 7H9 broth, may alter the susceptibility, most likely due to the decrease in pH. A more enriched broth that does not result in altered macrolide MICs has yet to be developed. The use of erm gene sequencing as a backup for indeterminate MIC results is probably the best current solution to improve phenotypic results.
We recommend that the CLSI should evaluate the current clarithromycin susceptibility breakpoints for M. abscessus subsp. abscessus, and we further propose that isolates with a clarithromycin MIC of 8 g/ml (currently considered resistant) (9) should have repeat MIC testing and/or erm gene sequencing performed. Sequencing of the erm(41) gene is preferred, as sequencing can produce an answer more quickly than repeating the MIC tests.
Current subspecies identification of M. abscessus isolates requires multigene sequencing, because the three subspecies have identical complete 16S rRNA genes and the presence of gene recombination for commonly studied gene targets, such as the hsp65 gene and the rpoB gene. Interestingly, to date, no recombination of the erm gene between subspecies has been identified, and recombination was not observed among the Ͼ100 clinical isolates of M. abscessus subsp. abscessus with erm gene sequences in the current study. Further support for the genetic stability of this gene comes from the growing body of data for M. abscessus subsp. massiliense (2, 4, 16) , indicating that most isolates of this subspecies carry exactly the same deletion mutant erm(41) allele irrespective of the source patients' geographic locations. This makes the erm gene a good candidate for subspecies identification. An added benefit would be preliminary determination of erm gene functionality pending the results of the slower susceptibility testing method.
Recently, Shallom et al. (16) described two strains of M. abscessus subsp. massiliense (C12040 and C182) with full-length functional erm(41) genes. However, these genes were highly unusual in that they were Ͼ1% mismatches to those of the type strains of M. abscessus subsp. abscessus and/or M. abscessus subsp. bolletii. To our knowledge, these are the only two isolates of M. abscessus subsp. massiliense with a functional erm gene which have been described in the literature to date (16) . Since the sequevars of erm in M. abscessus subsp. abscessus are recognized, one should be suspicious of the taxonomic status of an isolate with this degree of mismatch from the type strain erm gene. Sequencing of other genes would seem to indicate a horizontal gene transfer, and the isolate would be identified as a "subspecies abscessus/subspecies massiliense cross strain."
